Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, adenovirus infection could not break liver tolerance and induce AIH in Balb/c mice even in the presence of CYP2D6 antigen mimicry.
|
31794800 |
2020 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, either adenovirus/CYP2D6 or CCl<sub>4</sub>/CYP2D6 could induce the autoimmune response and AIH in the mice, leading to hepatic fibrosis.
|
29793131 |
2018 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the role of HLA-DR4 in the development of AIH by immunization of HLA-DR4 (DR4) transgenic non-obese diabetic (NOD) mice with DNA coding for human CYP2D6/FTCD fusion autoantigen.
|
27414259 |
2016 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model.
|
26924542 |
2016 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytochrome mono-oxygenase, CYP2D6, is the autoantigen associated with type 2 autoimmune hepatitis, and it shares homologies with multiple viruses that might promote self-intolerance by molecular mimicry.
|
25999246 |
2015 |
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis.
|
23200317 |
2013 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The liver-kidney 'microsomal' autoantigen reactive with cytochrome P450 2D6 distinguishes two serological types of AIH that appear pathogenetically distinct.
|
21072544 |
2011 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to identify possible environmental triggers for AIH, we analyzed for the first time the spreading of the anti-CYP2D6 antibody response over a prolonged period of time in AIH patients and in the CYP2D6 mouse model, in which mice infected with Adenovirus-human CYP2D6 (Ad-h2D6) develop antibodies with a similar specificity than AIH patients.
|
21795021 |
2011 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advances in the study of autoreactive T cells stem mostly from AIH type 2, where the main autoantigen, cytochrome P450IID6 (CYP2D6), is known to enable characterisation of antigen-specific immune responses.
|
20460892 |
2010 |
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CD4 T cells from patients with type 2 AIH positive for the predisposing HLA allele DRB1*0701 recognize seven regions of CYP2D6, five of which are also recognized by CD8 T cells.
|
18528928 |
2008 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A new epitope of CYP2D6 recognized by liver kidney microsomal autoantibody from japanese patients with autoimmune hepatitis.
|
16327157 |
2005 |
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anti-liver-kidney microsome type 1 (LKM1) autoantibodies directed against the cytochrome P450 2D6 (CYP2D6) are considered specific markers of type 2 autoimmune hepatitis, but are also found in 5% of sera from patients chronically infected by hepatitis C virus (HCV).
|
16037945 |
2005 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LKM1-positive sera obtained from 16 patients with AIH and 16 with HCV infection were used as probes to perform a complete epitope mapping of CYP2D6.
|
12077255 |
2002 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The autoantigen to anti-LKM-1 has been identified to be cytochrome P450 IID6 (CYP2D6) and the most frequently cited CYP2D6 antigenic sites of anti-LKM-1 in sera from autoimmune hepatitis type II patients spans the region aa 256-269.
|
11712862 |
2001 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The five CYP proteins did not react with sera from normal controls nor from patients with chronic hepatitis B. CYP2D6 reacted with sera from 100% (9/9) of AIH type II patients, 79% (19/24) of patients with anti-LKM-1-positive chronic hepatitis C, and 6.5% (2/31) of patients with anti-LKM-1-negative chronic hepatitis C. In contrast, CYP1A2 reacted with serum from one patient with AIH type I, CYP2E1 reacted with sera from two patients with AIH type I, one patient with anti-LKM-1-positive chronic hepatitis C, and two patients with anti-LKM-1-negative chronic hepatitis C, and CYP3A4 reacted with sera from one patient with AIH type II and one patient with anti-LKM-1-positive chronic hepatitis C. CYP2C9 did not react with any of the sera included in this study.
|
11204250 |
2000 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that anti-LKM antibodies in AIH and hepatitis C react with CYP2D6, as shown by their inhibitory activity, and that besides the known epitope 257-269 a further immunodominant epitope exists on CYP2D6 which is recognized by sera from patients with AIH II but hardly by sera from patients with hepatitis C.
|
10540193 |
1999 |
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, the sera of patients with autoimmune hepatitis type II and patients with chronic hepatitis C recognize different antigenic epitopes of the CYP2D6 molecule.
|
9719237 |
1998 |
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine this question, genomic DNA from peripheral lymphocytes (n = 9) and liver (n = 1) of 10 patients with anti-LKM-1 antibody was analysed by Southern blot for genetic association studies between a particular CYP2D6 haplotype and autoimmune hepatitis.
|
1346512 |
1992 |
Autoimmune hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |